Patents by Inventor Ya-Jen Chang
Ya-Jen Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180105547Abstract: The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived from Helicobacter pylori activates NKT cells in a CD1d-restricted fashion, and is protective against AHR in a model of allergen-induced asthma. The inventors further found that this protective effect can be transferred by NKT cells exposed to the glycolipid, and is associated with the expansion of a suppressive double-negative NKT cells and Foxp3+ TReg cells. The inventors also demonstrate herein that pretreatment of adult mice with a glycolipid derived from Helicobacter pylori partially suppresses airway hyperreactivity and inhibits BAL inflammation in an ozone-exposure model. Accordingly, provided herein are compositions and methods for the treatment and prevention of inflammatory diseases, such as asthma or autoimmune diseases, in a subject in need thereof.Type: ApplicationFiled: May 23, 2017Publication date: April 19, 2018Applicant: Children's Medical Center CorporationInventors: Dale T. Umetsu, Rosemarie Helena DeKruyff, Ya-Jen Chang, Petr Illarionov
-
Publication number: 20170319723Abstract: Disclosed herein is a radioimmune complex comprising an epidermal growth factor receptor (EGFR)-targeted antibody and a radioactive isotope of rhenium labeled thereon. The EGFR-targeted antibody is cetuximab or panitumumab.Type: ApplicationFiled: May 3, 2017Publication date: November 9, 2017Inventors: WAN-I KUO, KAI-HUNG CHENG, YI-SHU HUANG, SHENG-NAN LO, YA-JEN CHANG, TSUNG-TSE WU, WEI-CHUAN HSU, MING-HSIN LI, CHIH-HSIEN CHANG
-
Patent number: 9657046Abstract: The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived from Helicobacter pylori activates NKT cells in a CD1d-restricted fashion, and is protective against AHR in a model of allergen-induced asthma. The inventors further found that this protective effect can be transferred by NKT cells exposed to the glycolipid, and is associated with the expansion of a suppressive double-negative NKT cells and Foxp3+ TReg cells. The inventors also demonstrate herein that pre-treatment of adult mice with a glycolipid derived from Helicobacter pylori partially suppresses airway hyperreactivity and inhibits BAL inflammation in an ozone-exposure model. Accordingly, provided herein are compositions and methods for the treatment and prevention of inflammatory diseases, such as asthma or autoimmune diseases, in a subject in need thereof.Type: GrantFiled: May 24, 2011Date of Patent: May 23, 2017Assignees: Children's Medical Center Corporation, University of BirminghamInventors: Dale T. Umetsu, Rosemarie H. De Kruyff, Ya-Jen Chang, Petr Illarionov
-
Publication number: 20150297593Abstract: The invention provides methods, compositions, and kits featuring a c-Kit kinase inhibitor for use in preventing or treating virus-induced respiratory pathology.Type: ApplicationFiled: September 13, 2013Publication date: October 22, 2015Inventors: Dale T. Umetsu, Ya-Jen Chang, Rosemarie H. De Kruyff, Nicole Baumgarth
-
Publication number: 20140301996Abstract: The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived from Helicobacter pylori activates NKT cells in a CD1d-restricted fashion, and is protective against AHR in a model of allergen-induced asthma. The inventors further found that this protective effect can be transferred by NKT cells exposed to the glycolipid, and is associated with the expansion of a suppressive double-negative NKT cells and Foxp3+ TReg cells. The inventors also demonstrate herein that pre-treatment of adult mice with a glycolipid derived from Helicobacter pylori partially suppresses airway hyperreactivity and inhibits BAL inflammation in an ozone-exposure model. Accordingly, provided herein are compositions and methods for the treatment and prevention of inflammatory diseases, such as asthma or autoimmune diseases, in a subject in need thereof.Type: ApplicationFiled: May 24, 2011Publication date: October 9, 2014Applicants: UNIVERSITY OF BIRMINGHAM, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Dale T. Umetsu, Rosemarie Helena De Kruyff, Ya-Jen Chang, Petr Illarionov
-
Publication number: 20120295349Abstract: A mammal dedicated cell line is provided, which is a HepG2 hepatocellular carcinoma cell line (HepG2/NF-kB/Luc/sr39tk)1_18 obtained by co-transformation with NF-kB/Luc and NF-kB/sr39tk. Firstly, a successfully transformed pNF-kB/Luc HepG2 cell is obtained. Then, a dedicated cell line sensitive to TPA and MTX is generated by experimental screening Next, a plasmid construct carrying pNF-kB/sr39tk genome is introduced into the dedicated cell line by means of Superfect protocol. Finally, a HepG2 cell line co-expressing NF-kB/Luc and NF-kB/sr39tk is screened with G418 and ZEOCIN, and transformation result is confirmed by luminescence and radio activity. The (HepG2/NF-kB/Luc/sr39tk)1_18 obtained is suitable to screen drug for treating liver cancer and examine these cells by bioluminescence imaging and nuclear medicine imaging.Type: ApplicationFiled: July 23, 2012Publication date: November 22, 2012Applicant: Institute of Nuclear Energy Research Atomic Energy Council, Executive YuanInventors: TSUI-JUNG CHANG, Chih-Hsien Chang, Ya-Jen Chang, Te-Wei Lee, Tin-Yun Ho, Chien-yun Hsiang
-
Publication number: 20110158903Abstract: One pot process of preparing multifunctional liposome drug is provided. In this one pot process, liposome reacted with radionuclide labeled solution, chemotherapy drug, and targeted ligand at appropriate temperature. The product in this invention for preparation multifunctional liposome drugs in for imaging, delivery and targeting in cancer diagnosis and therapy has proved to be more simple, convenient, effective and easier than the prior art is.Type: ApplicationFiled: December 31, 2009Publication date: June 30, 2011Applicant: Institute of Nuclear Energy Research Atomic Energy Council, Executive YuanInventors: SHU-PEI CHIU, Te-Wei Lee, Chia-Yu Yu, Su-Jung Chen, Chung-Li Ho, Wei-Chuan Hsu, Ya-Jen Chang
-
Patent number: 7928077Abstract: The present disclosure relates to synthetic alpha-galactosyl ceramide (?-GalCer) analogs, and their use as immunotherapies. In one aspect. a method of activating a cytokine response in a subject includes administering an effective amount of a compound to a subject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1: or a pharmaceutically acceptable salt thereof; forming a complex between the compound and the antigen-presenting cell, wherein the formation of the complex results in the activation of a receptor on the lymphocyte; and activating the lymphocyte to produce the cytokine response.Type: GrantFiled: July 11, 2008Date of Patent: April 19, 2011Assignee: Academia SinicaInventors: Chi-Huey Wong, Alice Yu, Ya-Jen Chang, Kun-Hsien Lin, Jung-Tung Hung
-
Publication number: 20100216232Abstract: A mammal dedicated cell line is provided, which is a HepG2 hepatocellular carcinoma cell line (HepG2/NF-kB/Luc/sr39tk)1_18 obtained by co-transformation with NF-kB/Luc and NF-kB/sr39tk. Firstly, a successfully transformed pNF-kB/Luc HepG2 cell is obtained. Then, a dedicated cell line sensitive to TPA and MTX is generated by experimental screening Next, a plasmid construct carrying pNF-kB/sr39tk genome is introduced into the dedicated cell line by means of Superfect protocol. Finally, a HepG2 cell line co-expressing NF-kB/Luc and NF-kB/sr39tk is screened with G418 and ZEOCIN, and transformation result is confirmed by luminescence and radio activity. The (HepG2/NF-kB/Luc/sr39tk)1_18 obtained is suitable to screen drug for treating liver cancer and examine these cells by bioluminescence imaging and nuclear medicine imaging.Type: ApplicationFiled: July 21, 2009Publication date: August 26, 2010Applicant: Institute of Nuclear Energy Researh Atomic Energy Council, Executive YuanInventors: TSUI-JUNG CHANG, CHIH-HSIEN CHANG, YA-JEN CHANG, TE-WEI LEE, TIN-YUN HO, CHIEN-YUN HSIANG
-
Publication number: 20100008954Abstract: The present disclosure relates to synthetic alpha-galactosyl ceramide (?-GalCer) analogs, and their use as immunotherapies. In one aspect. a method of activating a cytokine response in a subject includes administering an effective amount of a compound to a subject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1: or a pharmaceutically acceptable salt thereof; forming a complex between the compound and the antigen-presenting cell, wherein the formation of the complex results in the activation of a receptor on the lymphocyte; and activating the lymphocyte to produce the cytokine response.Type: ApplicationFiled: July 11, 2008Publication date: January 14, 2010Inventors: Chi-Huey Wong, Alice Yu, Ya-Jen Chang, Kun-Hsien Lin, Jung-Tung Hung
-
Publication number: 20080260774Abstract: The present disclosure relates to synthetic alpha-galactosyl ceramide (?-GalCer) analogs, and their use as immunotherapies.Type: ApplicationFiled: April 14, 2008Publication date: October 23, 2008Inventors: Chi-Huey Wong, Alice Yu, Ya-Jen Chang
-
Kit for preparation of nano-targeted liposome drug in combined radionuclide therapy and chemotherapy
Publication number: 20080226546Abstract: This invention is to manufacture a kit for preparation of nano-targeted liposome drugs in combined chemotherapy and radionuclide therapy. It is a kit consisting of three components: (1) A 10 ml vial A which contains BMEDA, gluconate acetate, SnCl2. (2) A 10 ml vial B which contains DSPC, cholesterol, DSPE-PEG, and Doxorubicin(DXR) (or Daunorubicin, Vinolbine). (3) A 10 ml vial C which contains 188ReO4? (or 186ReO4?) solution. The procedure of using the kit is as follows: (1) Remove the contents of the 188ReO4? (or 186ReO4?) solution from vial C. (2) Inject the 188ReO4? (or 186ReO4?) solution into the vial A, and the mixtures react in appropriate temperature. (3) Remove the contents of the 188Re-BMEDA (or 186Re-BMEDA) solution from vial A. (4) Inject the 188Re-BMEDA (or 186Re-BMEDA) solution into the vial B, and the mixtures react in appropriate temperature. The reconstituted solution in the vial B is applied to combine bimodality radiochemotherapy for treatment of tumor and ascites.Type: ApplicationFiled: March 18, 2007Publication date: September 18, 2008Inventors: Te-Wei Lee, Ya-Jen Chang, Liang-Cheng Chen, Chia-Yu Yu, Shu-Pei Chiu, Shu-Ling Chen, Tsai-Yueh Luo, Chih-Hsien Chang, Gann Ting